Evidence map›Paper›PMID 37660904›Full record

ArticleThe Journal of biological chemistry2023

The RavA-ViaA chaperone complex modulates bacterial persistence through its association with the fumarate reductase enzyme.

Vaibhav Bhandari, Sean E Reichheld, Scott Houliston, Alexander Lemak, Cheryl H Arrowsmith, Simon Sharpe, Walid A Houry

Open access · goldAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Structural modeling and biochemical characterization of MSMEG_0748, a MoxR ATPase fromComputational and structural biotechnology journal · 2025
    Article
  3. Molecular Characterization of the MoxR AAA+ ATPase ofInternational journal of molecular sciences · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Vaibhav BhandariDepartment of Biochemistry, University of Toronto, Toronto, Ontario, Canada.
Sean E ReichheldMolecular Medicine Program, The Hospital for Sick Children, Toronto, Ontario, Canada.
Scott HoulistonPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
Alexander LemakPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
Cheryl H ArrowsmithPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada; Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada; Structural Genomics Consortium, Toronto, Ontario, Canada.
Simon SharpeDepartment of Biochemistry, University of Toronto, Toronto, Ontario, Canada; Molecular Medicine Program, The Hospital for Sick Children, Toronto, Ontario, Canada.
Walid A HouryDepartment of Biochemistry, University of Toronto, Toronto, Ontario, Canada; Department of Chemistry, University of Toronto, Toronto, Ontario, Canada. Electronic address: walid.houry@utoronto.ca.
University Health Network · CAUniversity of Toronto · CAHospital for Sick Children · CA

Funding

CIHR
6 · The paper itself

Abstract

Regulatory ATPase variant A (RavA) is a MoxR AAA+ protein that functions together with a partner protein termed von Willebrand factor type A interacting with AAA+ ATPase (ViaA). RavA-ViaA are functionally associated with anaerobic respiration in Escherichia coli through interactions with the fumarate reductase (Frd) electron transport complex. Through this association, RavA and ViaA modulate the activity of the Frd complex and, hence, are proposed to have chaperone-like activity. However, the functional role of RavA-ViaA in the cell is not yet well established. We had demonstrated that RavA-ViaA can sensitize E. coli cells to sublethal concentrations of the aminoglycoside class of antibiotics. Since Frd has been associated with bacterial persistence against antibiotics, the relationship of RavA-ViaA and Frd was explored within this context. Experiments performed here reveal a function of RavA-ViaA in bacterial persistence upon treatment with antibiotics through the association of the chaperone complex with Frd. As part of this work, the NMR structure of the N-terminal domain of ViaA was solved. The structure reveals a novel alpha helical fold, which we name the VAN fold, that has not been observed before. We show that this domain is required for the function of the chaperone complex. We propose that modulating the levels of RavA-ViaA could enhance the susceptibility of Gram-negative bacteria to antibiotics.

Indexed as

Adenosine TriphosphatasesDrug Resistance, BacterialEscherichia coli ProteinsMolecular ChaperonesOxidoreductasesAnaerobiosisAnti-Bacterial AgentsKanamycinMicrobial Sensitivity TestsNuclear Magnetic Resonance, BiomolecularProtein Conformation, alpha-HelicalProtein DomainsAdenosine TriphosphatasesAnti-Bacterial AgentsEscherichia coli ProteinsKanamycinMolecular ChaperonesOxidoreductasesRavA protein, E coliViaA protein, E coliAAA+ proteinsbacterial persistenceMoxRNMR structureRavAViaAvon Willebrand factor type A domain

Identifiers

PMID37660904
PMCPMC10585395
OpenAlexW4386401796

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.